ZAP-AIRTMMICRONIZER: IMPACT ON NEBULIZED SALBUTAMOL SULPHATE AND IPRATROPIUM BROMIDE PARTICLE SIZE

MUHAMMAD IZZUDDIN ZAMERY; SHARIZA SAHUDIN; SHAHARIZUAN ABDUL RAHMAN; ALBERT KOW

doi:10.22159/ijap.2024v16i5.51277

Authors

MUHAMMAD IZZUDDIN ZAMERY Department of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam Campus, Bandar Puncak Alam, Selangor-42300, Malaysia https://orcid.org/0000-0002-2591-1690
SHARIZA SAHUDIN Department of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam Campus, Bandar Puncak Alam, Selangor-42300, Malaysia. Atta-Ur-Rahman Institute of Natural Product Discovery (AuRIns), Universiti Teknologi MARA, Puncak Alam Campus, Bandar Puncak Alam, Selangor-42300, Malaysia https://orcid.org/0000-0002-1784-3608
SHAHARIZUAN ABDUL RAHMAN Department of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam Campus, Bandar Puncak Alam, Selangor-42300, Malaysia
ALBERT KOW TAKO Astatic Technology Sdn Bhd, No. 15, Jalan Kesuma 2/2, Bandar Tasik Kesuma, Beranang, Selangor-43700, Malaysia

DOI:

https://doi.org/10.22159/ijap.2024v16i5.51277

Keywords:

Particle size' 'COPD' 'Salbutamol sulphate', Ipratropium bromide

Abstract

Objective: This study aimed to investigate the effect of the patented Zap-Air™ Micronizer on the particle size reduction of salbutamol sulphate (Ventolin), ipratropium bromide (Atrovent), and their combination (Combivent) nebulizing solutions.

Methods: The study used an Omron Compressor Nebulizer NE-C28 and compressed oxygen at flow rates of 3L and 6L per minute. Particle size analysis was conducted using Malvern Spraytec Laser Diffraction System to measure DV4 (4% of particles in the sample), DV50 (50% of particles in the sample), DV90 (90% of particles in the sample). Drug deposition analysis was performed using the Next Generation Pharmaceutical Impactor (NGI) with High-Performance Liquid Chromatography (HPLC) to analyze the content at each stage.

Results: The Zap-Air™ Micronizer effectively reduced the particle size of salbutamol sulphate and ipratropium bromide to less than 2 μm. Both Unit 1 and Unit 2 micronizers showed significant particle size reduction, with the average size of 50% of particles (DV50) being below 1 μm. Drug release intensity was significantly reduced when using the micronizers compared to the nebulizer alone.

Conclusion: The Zap-Air™ Micronizer has the potential to enhance drug delivery and therapeutic effects in the treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD) by improving the deposition of salbutamol sulphate and ipratropium bromide into the smaller airways of the lungs.

Downloads

Download data is not yet available.

References

Stein SW, Thiel CG. The history of therapeutic aerosols a chronological review. J Aerosol Med Pulm Drug Deliv. 2017;30(1):20-41. doi: 10.1089/jamp.2016.1297, PMID 27748638.

Hickey AJ. Back to the future: inhaled drug products. J Pharm Sci. 2013;102(4):1165-72. doi: 10.1002/jps.23465, PMID 23381932.

Newman SP. Fine particle fraction: the good and the bad. J Aerosol Med Pulm Drug Deliv. 2022;35(1):2-10. doi: 10.1089/jamp.2021.29056.spn, PMID 35171044.

Clark AR. Limitations of pulmonary drug delivery. In: Dhand R. editor. ISAM textbook of aerosol medicine. Werne, North Rhine-Westphalia, Germany: International society for aerosols in medicine; 2015. p. 1081-101.

Clark AR. Medical aerosol inhalers past present and future. Aerosol Sci Technol. 1995;22(4):374-91. doi: 10.1080/02786829408959755.

Hinds WC. Aerosol technology: properties, behavior, and measurement of airborne particles. 2nd ed. New York: John Wiley & Sons; 2012.

El Baou C, Di Santostefano RL, Alfonso Cristancho R, Suarez EA, Stempel D, Everard ML. Correction to effect of inhaled corticosteroid particle size on asthma efficacy and safety outcomes a systematic literature review and meta analysis. BMC Pulm Med. 2017;17(1):172. doi: 10.1186/s12890-017-0507-2.

Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of β2-agonist particle size. Am J Respir Crit Care Med. 2005;172(12):1497-504. doi: 10.1164/rccm.200410-1414OC, PMID 16192448.

Haussermann S, Acerbi D, Brand P, Herpich C, Poli G, Sommerer K. Lung deposition of formoterol HFA (atimos/forair) in healthy volunteers asthmatic and COPD patients. J Aerosol Med. 2007;20(3):331-41. doi: 10.1089/jam.2007.0613, PMID 17894539.

Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane 134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone a cross-over study in healthy volunteers. Chest. 2002;122(2):510-6. doi: 10.1378/chest.122.2.510, PMID 12171824.

Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998;12(6):1346-53. doi: 10.1183/09031936.98.12061346, PMID 9877489.

Hillyer EV, Price DB, Chrystyn H, Martin RJ, Israel E, van Aalderen WM. Harmonizing the nomenclature for therapeutic aerosol particle size a proposal. J Aerosol Med Pulm Drug Deliv. 2018;31(2):111-3. doi: 10.1089/jamp.2017.1396, PMID 29182483.

Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998;12(6):1346-53. doi: 10.1183/09031936.98.12061346, PMID 9877489.

Muralidharan P, Malapit M, Mallory E, Hayes D, Mansour HM. Inhalable nanoparticulate powders for respiratory delivery. Nanomedicine. 2015;11(5):1189-99. doi: 10.1016/j.nano.2015.01.007, PMID 25659645.

Heerfordt CK, Ronn C, Harboe ZB, Ingebrigtsen TS, Svorre Jordan A, Wilcke JT. Inhalation devices and inhaled corticosteroids particle size influence on severe pneumonia in patients with chronic obstructive pulmonary disease a nationwide cohort study. BMJ Open Respir Res. 2023;10(1):e001814. doi: 10.1136/bmjresp-2023-001814, PMID 37775111.

Van der Molen T, Postma DS, Martin RJ, Herings RM, Overbeek JA, Thomas V. Effectiveness of initiating extrafine particle versus fine particle inhaled corticosteroids as asthma therapy in the Netherlands. BMC Pulm Med. 2016;16(1):80. doi: 10.1186/s12890-016-0234-0, PMID 27184175.

Abdul Hamid MF, Ahmad A, Mohamad Jailaini MF, Soelar SA, Nik Abeed NN, Hau NB. The effect of fine particle size and extrafine particle size inhaled corticosteroid in reducing airway resistance in asthmatic patients. Proceedings of the Singap Healthc. 2023;32:1-7. doi: 10.1177/20101058231167250.

Gessner C, Trinkmann F, Bahari Javan S, Hovelmann R, Bogoevska V, Georges G. Effectiveness of extrafine single inhaler triple therapy in chronic obstructive pulmonary disease (COPD) in Germany the trioptimize study. Int J Chron Obstruct Pulmon Dis. 2022;17:3019-31. doi: 10.2147/COPD.S382405, PMID 36483674.

Abdelrahim ME, Chrystyn H. Aerodynamic characteristics of nebulized terbutaline sulphate using the next generation impactor (NGI) and CEN method. J Aerosol Med Pulm Drug Deliv. 2009;22(1):19-28. doi: 10.1089/jamp.2008.0650, PMID 19392586.

Berg E, Lamb P, Ali A, Dennis J, Tservistas M, Mitchell J. Assessment of the need to coat particle collection cups of the NGI to mitigate droplet bounce when evaluating nebuliser produced droplets. Pharm Europa Sci Notes. 2008;1:21-6.

Raj SM, Jamakandi VG, Jalalpure SS, Ronad PM. Simultaneous detection and quantification of bronchodilators in pure form and from in vitro drug release of a novel combinational formulation. J Appl Pharm Sci. 2020;10(8):131-8.

Abyadeh M, Karimi Zarchi AA, Faramarzi MA, Amani A. Evaluation of factors affecting size and size distribution of chitosan electrosprayed nanoparticles. Avicenna J Med Biotechnol. 2017;9(3):126-32. PMID 28706607.

Ravendran N, Chou PM. Effect of voltage and anodizing time on nano colloidal silver. J Phys Conf Ser. 2021;2120(1):012018. doi: 10.1088/1742-6596/2120/1/012018.

Javad PV, Neda G, Ebrahimian A. The effect of the anodization voltage on the geometrical characteristics and photocatalytic activity of nanotube arrays. Nano Struct Nano Objects. 2016;8:7-14. doi: 10.1016/j.nanoso.2016.09.001.

Ahmet Y, Saadet G, Mustafa E. Growth of ZnO nanoflowers: effects of anodization time and substrate roughness on structural, morphological, and wetting properties. J Aust Ceram Soc. 2019;56:995-1003.

Mushtaq K, Chou PM, Lai CW. Review on the synthesis methods of nano-tungsten oxide dihydrate colloid. MATEC Web Conf. 2021;335:03008. doi: 10.1051/matecconf/202133503008.

Zeng W, Guo P, Jiang P, Liu W, Hong T, Chen C. Combination of microfluidic chip and electrostatic atomization for the preparation of drug loaded core shell nanoparticles. Nanotechnology. 2020;31(14):145301. doi: 10.1088/1361-6528/ab6236, PMID 31841998.

Abdelrahim ME. Aerodynamic characteristics of nebulized terbutaline sulphate using the andersen cascade impactor compared to the next generation impactor. Pharm Dev Technol. 2011;16(2):137-45. doi: 10.3109/10837450903511194, PMID 20100034.

Van den Berge M, Ten Hacken NH, Cohen J, Douma WR, Postma DS. Small airway disease in asthma and COPD clinical implications. Chest. 2011;139(2):412-23. doi: 10.1378/chest.10-1210, PMID 21285055.

Usmani OS, Barnes PJ. Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease. Ann Med. 2012;44(2):146-56. doi: 10.3109/07853890.2011.585656, PMID 21679101.

Scichilone N, Spatafora M, Battaglia S, Arrigo R, Benfante A, Bellia V. Lung penetration and patient adherence considerations in the management of asthma role of extra fine formulations. J Asthma Allergy. 2013;6:11-21. doi: 10.2147/JAA.S14743, PMID 23378776.

Corradi M, Chrystyn H, Cosio BG, Pirozynski M, Loukides S, Louis R. Nexthaler an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma. Expert Opin Drug Deliv. 2014;11(9):1497-506. doi: 10.1517/17425247.2014.928282, PMID 24921434.

Dhillon S, Keating GM. Beclometasone dipropionate formoterol in an HFA-propelled pressurised metered dose inhaler. Drugs. 2006;66(11):1475-84. doi: 10.2165/00003495-200666110-00005, PMID 16906779.

Khan PA, Sujala A, Nousheen BS, Fatima AF, Ala HT, Reddy AP. A comparative evaluation of the efficacy of triple drug therapy with dual drug therapy in COPD patients. Int J Pharm Pharm Sci. 2018;10(4):105-9. doi: 10.22159/ijpps.2018v10i4.24529.

Sarumathy S, Sasidharan SL, Shaik M, Sandeep G, Rajasekhar V, Damodharan N. A clinical study on safety and efficacy of formoterol and tiotropium combination compared to formoterol and tiotropium with roflumilast combination in treatment of moderate to severe chronic obstructive pulmonary disease patients. Asian J Pharm Clin Res. 2018;11(3):184-6. doi: 10.22159/ajpcr.2018.v11i3.21871.